Transient Receptor Potential Vanilloid 1 Activation Enhances Gut Glucagon-Like Peptide-1 Secretion and Improves Glucose Homeostasis

  1. Zhiming Zhu
  1. Department of Hypertension and Endocrinology, Center for Hypertension and Metabolic Diseases, Daping Hospital, Third Military Medical University, Chongqing Institute of Hypertension, Chongqing, China
  1. Corresponding author: Zhiming Zhu, zhuzm{at}yahoo.com.
  1. P.W. and Z.Y. contributed equally to this study.

Abstract

Type 2 diabetes mellitus (T2DM) is rapidly prevailing as a serious global health problem. Current treatments for T2DM may cause side effects, thus highlighting the need for newer and safer therapies. We tested the hypothesis that dietary capsaicin regulates glucose homeostasis through the activation of transient receptor potential vanilloid 1 (TRPV1)-mediated glucagon-like peptide-1 (GLP-1) secretion in the intestinal cells and tissues. Wild-type (WT) and TRPV1 knockout (TRPV1−/−) mice were fed dietary capsaicin for 24 weeks. TRPV1 was localized in secretin tumor cell-1 (STC-1) cells and ileum. Capsaicin stimulated GLP-1 secretion from STC-1 cells in a calcium-dependent manner through TRPV1 activation. Acute capsaicin administration by gastric gavage increased GLP-1 and insulin secretion in vivo in WT but not in TRPV1−/− mice. Furthermore, chronic dietary capsaicin not only improved glucose tolerance and increased insulin levels but also lowered daily blood glucose profiles and increased plasma GLP-1 levels in WT mice. However, this effect was absent in TRPV1−/− mice. In db/db mice, TRPV1 activation by dietary capsaicin ameliorated abnormal glucose homeostasis and increased GLP-1 levels in the plasma and ileum. The present findings suggest that TRPV1 activation–stimulated GLP-1 secretion could be a promising approach for the intervention of diabetes.

Type 2 diabetes mellitus (T2DM) has rapidly become a serious global health problem (1,2). T2DM is characterized by a defect in insulin secretion and/or insulin sensitivity, which commonly requires multiple pharmacotherapies (3). Current strategies for T2DM treatments may cause undesirable effects, such as weight gain and hypoglycemia, but have little effect on its progression (4,5). An incretin-based therapy is currently used to manage hyperglycemia and is available in two different regimens, dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) agonists (6,7). These agents produce a glucose-dependent increase in insulin secretion and glucagon suppression, leading to lowering blood glucose (8,9). GLP-1 is a potent incretin hormone produced in L-cells of the distal ileum and colon (9). Dietary factors, including glucose, fatty acids, and fiber, are known to increase the mRNA expression of GLP-1 and stimulate the GLP-1 release (1012). However, circulating GLP-1 is short-lived due to inactivation by the enzyme DPP-4 (13). Thus, it is a challenge to develop long-acting selective GLP-1 analogs and DPP-4 inhibitors. One option is to target selective GLP-1 secretagogues in the intestinal tract through dietary intervention.

Administration of capsaicin, a major pungent ingredient in chili peppers, regulates insulin secretion and glucose homeostasis in animal experiments and human studies (1419). Transient receptor potential vanilloid subfamily 1 (TRPV1), a nonselective cation channel, is a specific receptor for capsaicin (20). TRPV1 is expressed in islet β-cells, neurons, rat pancreas, and rat β-cell lines RIN and INS1 (18,2123). Both the early insulin secretory response to intravenous glucose and glucose elimination were potentiated in mice after capsaicin administration (23). Purified capsaicin caused a decrease in blood glucose concentrations in dogs during an oral glucose tolerance test and a concomitant elevation in plasma insulin levels (19). In rats, subcutaneous administration of capsaicin increased insulin secretion and plasma insulin concentrations in a dose-dependent manner (18). The oral application of capsaicin also increases glucose absorption and utilization in healthy humans (17). Ahuja et al. (24) reported that regular consumption of chili attenuated postprandial hyperinsulinemia in humans. Although several studies showed that capsaicin administration lowered blood glucose and increased insulin secretion, the capsaicin-sensitive sensory fibers in the islets of Langerhans contribute to defective insulin secretion in the Zucker diabetic rat (21). Furthermore, a mutant TRPV1 in sensory neurons initiates a chronic and progressive β-cell stress, which induces islet cell inflammation in type 1 diabetic mice (22). These studies indicated that in nonneuronal tissues, TRPV1 may regulate insulin secretion and glucose homeostasis through a distinct mechanism beyond inflammation in β-cells caused by the TRPV1+ sensory neurons.

Secretin tumor cell-1 (STC-1) cells exhibit a phenotype similar to enteroendocrine L-cells and secrete several incretin hormones including GLP-1. The STC-1–mediated GLP-1 release was triggered by the initiation of calcium influx, which may involve a putative ion channel (12). Interestingly, TRPV1 has been found to be present on the rectum and distal colon (25). A human study showed that an acute lunch that contained capsaicin increased plasma GLP-1 levels (14). TRPV1 is a Ca2+-permeable cation channel that is activated by capsaicin. Physiological concentrations of insulin regulate TRPV1 protein expression and activity (26). However, it is largely unknown whether the effects of dietary capsaicin on glucose homeostasis are linked with the triggering of GLP-1 production by intestinal TRPV1. Therefore, we hypothesized that TRPV1 activation enhanced endogenous GLP-1 production in the intestinal tissues, which in turn promoted insulin secretion and regulated glucose homeostasis. In this study, we provide experimental evidence that TRPV1 activation by dietary capsaicin can augment GLP-1 secretion, which increases plasma insulin levels, reduces blood glucose levels in C57BL/6J mice but not in TRPV1-deficient mice, and prevents hyperglycemia in db/db diabetic mice.

RESEARCH DESIGN AND METHODS

Animal treatment.

C57BL/6J and TRPV1−/− mice were purchased from The Jackson Laboratory (Bar Harbor, ME). The db/db mice and age-matched lean littermate mice (C57BL/KsJ) were purchased from Model Animal Research Center (Nanjing University). Mice were housed under a 12-h/12-h day/night cycle with free access to food and water. Animals were given the normal standard chow (control group) or normal chow plus 0.01% capsaicin (capsaicin group). The Institute’s Animal Care and Use Committee approved all animal protocols.

Intraperitoneal glucose tolerance and insulin tolerance tests.

Intraperitoneal glucose tolerance test (IPGTT) was performed (27). After an overnight fast (14 h), glucose (2 g/kg body weight) was administered via injection into the peritoneal cavity, and blood was obtained from the tail vein at 0, 30, 60, and 120 min after glucose administration. Blood glucose levels were determined using the OneTouch Ultra blood glucose meter (LifeScan). Intraperitoneal insulin tolerance test was performed in fed mice on a different day. Humulin R (0.75 units/kg body weight) (Eli Lilly) in sterile saline was administered via injection into the peritoneal cavity (27). Glucose levels were determined on the tail blood at 0, 15, 30, 45, and 60 min after insulin injection.

Continuous monitoring of blood glucose in conscious mice.

To definitely determine daily average blood glucose level in mice, we used the Continuous Glucose Monitoring System (CGMS; Medtronic MiniMed, Northridge, CA) to continuously measure blood glucose for 24 h (detect range: 2.2–22.2 mmol/L) as described (28). CGMS is a U.S. Food and Drug Administration–approved device for 24-h recording blood glucose levels. The electrical signals were collected every 10 s, averaged, and saved to memory of the cable-tethered glucose monitor every 5 min. The data stored in the monitor were periodically downloaded into a computer for later analysis.

A method for implantation of the subcutaneous glucose sensor in mice was established (28). The fur on the lower back was shaved and the skin sterilized with an iodine pad, followed by washing with a 70% ethanol pad. The glucose sensor was inserted subcutaneously and fixed to skin using tissue glue. The mouse was then housed individually in a cage and allowed free access to water and food. The glucose signal was recorded by the glucose monitor placed outside the cage via a cable tethered to the mouse. Three to four measurements of blood glucose were performed during the daytime. Blood glucose levels were determined using the OneTouch Ultra blood glucose meter (LifeScan), blood was obtained from the tail, and the blood glucose values were input into the monitor to calibrate the glucose level. To minimize the effect of sensor implantation on blood glucose, the data recorded by the glucose sensor in the first 5 h were discarded.

Cell culture.

STC-1 cell line was purchased from the Cell Bank of Type Culture Collection of the Shanghai Institute of Cell Biology, Chinese Academy of Sciences. Cell line was maintained in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum and 1% antibiotics (11).

GLP-1 secretion in vitro.

STC-1 cells were washed three times in Hanks’ balanced salt solution (137.93 mmol/L NaCl, 5.33 mmol/L KCl, 4.17 mmol/L NaHCO3, 1.26 mmol/L CaCl2, 0.493 mmol/L MgCl2, 0.407 mmol/L MgSO4, 0.441 mmol/L KH2PO4, 0.338 mmol/L Na2HPO4, and 5.56 mmol/L d-glucose), and then incubated in growth medium for 60 min at 37°C in Hanks’ balanced salt solution containing varied concentrations of capsaicin. After incubation, conditioned medium was collected, and the concentration of GLP-1 was determined using a specific GLP-1 (7–36) amide enzyme immunoassay kit (Applygen Technologies Inc., Beijing, China) (11).

GLP-1 and insulin secretion in vivo.

In acute studies, 8-week-old male C57BL/6J mice and age-matched male TRPV1−/− mice were given glucose (2 g/kg body weight) solution by oral gavage through a stomach tube after being deprived of food for 14 h. Sixteen mice were randomly divided into four groups: the control group given only a glucose solution; the capsaicin group given a glucose solution containing 1 μmol/L capsaicin; the resiniferatoxin (RTX) group given a glucose solution containing 1 μmol/L RTX; and the capsaicin plus 5′-iodo-resiniferatoxin (iRTX) group given a glucose solution with 1 μmol/L capsaicin plus 1 μmol/L iRTX. After 30 min of oral glucose challenge, blood was taken from the central vein of mice under anesthesia with diethyl ether. Plasma was obtained by centrifugation of heparinized blood at 4°C for 20 min at 1,200 g and subjected to enzyme immunoassays (11). In chronic studies, after the treatment of dietary capsaicin, the mice were given only a glucose solution (2 g/kg body weight).

Western blotting and immunofluorescence analysis.

Western blotting analysis of GLP-1 (7–36) and TRPV1 was performed using standard procedures as described (2931). Glyceraldehyde-3-phosphate dehydrogenase was used as a loading control. Immunofluorescence for TRPV1 and GLP-1 (7–36) in STC-1 cells and mice ileum was performed (29). All of the primary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).

Pancreatic and islet histological examination.

The whole pancreas was dissected free from fat and other nonpancreatic tissue immediately after the mouse was killed. Whole pancreas from each group was stained with hematoxylin and eosin and anti-insulin antibody (Santa Cruz Biotechnology) (32).

Statistics.

Results are expressed as mean ± SEM. Comparisons between groups were analyzed using one-way ANOVA with Bonferroni’s multiple comparison post hoc tests or Student t test, whenever appropriate. A P value <0.05 was considered as statistically significant.

RESULTS

TRPV1 and GLP-1 in STC-1 cells and mice ileum.

TRPV1 is expressed in sensory nerves, dorsal root ganglia, bladder, blood vessels, and gut (25,33). GLP-1 originates from the lower intestines, particularly from the ileum (9). STC-1 line, a mouse enteroendocrine cell line of intestinal origin, secretes GLP-1 upon nutrient intake (11,34). However, it is unknown whether TRPV1 is expressed in intestinal cells and ileum. Immunofluorescence images indicated that TRPV1 and GLP-1 colocalized in the STC-1 cell and mouse ileum (Fig. 1A and B). The expression of TRPV1 protein was clearly detected by immunoblot analysis in both cultured STC-1 cells and freshly isolated ileum from C57BL/6J mice (Fig. 1C). These results suggest that TRPV1 is present in the GLP-1–secreting intestinal cells and tissues.

FIG. 1.

Colocalization of TRPV1 channels and GLP-1 in STC-1 cells and the mouse ileum. A and B: STC-1 cells and mice ileum sections were incubated with primary antibodies, anti-TRPV1, anti–GLP-1 (7–36), then incubated with a secondary antibody. The negative controls were only incubated with the secondary antibodies. Immunofluorescence images indicated TRPV1 channels (green) and GLP-1 (red) colocalized in STC-1 cells (scale bars, 20 μm) and the mouse ileum (scale bars, 50 μm; arrowheads point to GLP-1– and TRPV1-positive cells). No labeling was found in the absence of primary antibodies. C: Representative immunoblots of TRPV1 protein in STC-1 cells and the mouse ileum. KD, kilodalton. (A high-quality digital representation of this figure is available in the online issue.)

Activation of TRPV1 stimulates GLP-1 release in STC-1 cells.

Previous studies showed that an increase in intracellular calcium levels is associated with GLP-1 secretion (11,34). We examined whether TRPV1 activation promotes GLP-1 secretion from STC-1 cells in a calcium-dependent manner. We first showed that capsaicin stimulated GLP-1 release from STC-1 cells in a dose-dependent manner (Fig. 2A), which was antagonized by the TRPV1-specific blockers capsazepine or iRTX (Fig. 2B). We next investigated whether the effects of capsaicin on GLP-1 secretion were associated with changes in the intracellular calcium levels. The removal of intracellular calcium with 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA) or extracellular calcium with EGTA inhibited the capsaicin-induced GLP-1 secretion and GLP-1 protein level in STC-1 cells (Fig. 2C and D). To examine whether voltage-dependent Ca2+ channel is involved, two L-type Ca2+ channel blockers, nifedipine and verapamil, were used. Both blockers partially attenuated capsaicin-induced GLP-1 secretion in STC-1 cells (Supplementary Fig. 1). The present results indicate that capsaicin stimulates GLP-1 secretion from STC-1 cells through TRPV1-mediated Ca2+ increase.

FIG. 2.

Activation of TRPV1 stimulates GLP-1 release in STC-1 cells A: Capsaicin (Cap) induced GLP-1 secretion in STC-1 cells in a dose-dependent manner. **P < 0.01 versus control (Cont), n = 6. B: Capsaicin (1 μmol/L) and RTX (1 μmol/L) induced GLP-1 secretion in STC-1 cells, which was blocked by the TRPV1 antagonists iRTX and capsazepine. **P < 0.01 versus control; n = 6. C: The Ca2+ chelators BAPTA or EGTA inhibited capsaicin-induced GLP-1 secretion from STC-1 cells. **P < 0.01 versus capsaicin; n = 6. D: The capsaicin-induced increased GLP-1 protein level was inhibited by iRTX, BAPTA, and EGTA in cultured STC-1 cells. *P < 0.05, **P < 0.01 versus capsaicin; n = 3. These data are represented as mean ± SEM and were analyzed with a Student unpaired t test.

Acute capsaicin administration increases GLP-1 secretion in vivo through TRPV1 activation.

Capsicum frutescens or dietary capsaicin has been shown to affect glucose homeostasis (15,16,18,19). It is unknown whether the acute effects of capsaicin on GLP-1 secretion can be detected in vivo by TRPV1 stimulation. We examined the effects of intragastric administration of capsaicin on the circulating levels of peptide YY (PYY), glucose-dependent insulinotropic polypeptide, and glucagon. Fasting mice were challenged with glucose (2 g/kg) and capsaicin (1 μmol/L). The plasma PYY, glucose-dependent insulinotropic polypeptide, and glucagon levels at 30 min were not different in wild-type (WT) mice with and without capsaicin administration (Supplementary Fig. 2). By contrast, administration of capsaicin or another TRPV1 agonist, RTX, increased GLP-1 secretion 30 min after glucose challenge, and this effect was inhibited by the TRPV1 antagonist iRTX in WT mice (Fig. 3A). However, the effect of increased GLP-1 secretion was absent in TRPV1−/− mice (Fig. 3B). A similar effect of capsaicin on plasma insulin levels was observed (Fig. 3C and D). In the absence of glucose challenge, capsaicin also slightly increased the GLP-1 levels, although plasma GLP-1 level is much lower than in the presence of glucose challenge (Supplementary Fig. 3). We next examined the TRPV1 action using the selective GLP-1 receptor antagonist, exendin (9–39). The plasma insulin levels were significantly decreased after intraperitoneal injection of exendin (9–39) (10 µg/mice) before glucose challenge. In addition, the effect of oral capsaicin on plasma levels of insulin was suppressed by pretreatment with exendin (9–39) in WT mice (Supplementary Fig. 4A). Oral administration of DPP -4 inhibitor sitagliptin (3 mg/kg) prevented GLP-1 degradation, which may enhance the effects of capsaicin (Supplementary Fig. 5). These results indicate that acute capsaicin administration increases GLP-1 secretion in vivo through TRPV1 activation.

FIG. 3.

Capsaicin (Cap) administration increases GLP-1 secretion in vivo in a TRPV1-dependent manner. A and B: Plasma GLP-1 levels after acute administration of capsaicin (1 μmol/L) or RTX (1 μmol/L) with glucose (2 g/kg) in the presence or absence of iRTX (1 μmol/L) in 8-week-old male TRPV1 knockout (TRPV1−/−) or WT mice. *P < 0.05 versus control (Cont); n = 4. C and D: The plasma insulin levels in WT and TRPV1−/− mice were also quantified after a 30-min glucose challenge. Student unpaired t test: *P < 0.05.

TRPV1 activation by chronic dietary capsaicin improves glucose tolerance.

TRPV1 plays a role in the regulation of glucose homeostasis, but the results are inconsistent (35). The current study examined whether chronic dietary capsaicin affects glucose tolerance in WT and TRPV1−/− mice. WT mice with dietary capsaicin had a lower fasting glucose levels and an improvement of IPGTT compared with WT mice without dietary capsaicin (Fig. 4A). However, there were no changes in TRPV1−/− mice with or without dietary capsaicin (Fig. 4B). The body weight was similar in WT and TRPV1−/− mice with and without dietary capsaicin (Supplementary Fig. 6). We next investigated whether a glucose challenge increased GLP-1 secretion in mice treated with dietary capsaicin. Plasma GLP-1 levels and GLP-1 protein expression in the ileum were higher in WT but not in TRPV1−/− mice with chronic dietary capsaicin (Fig. 4C–E). The present results suggest that improvements in glucose tolerance by chronic dietary capsaicin are associated with GLP-1 secretion mediated by TRPV1 activation.

FIG. 4.

The improvement of glucose tolerance by dietary capsaicin (Cap) is associated with TRPV1. A and B: An IPGTT (2 g/kg) and the fasting blood glucose levels in WT and TRPV1−/− mice fed chow with or without capsaicin for 24 weeks. *P < 0.05, **P < 0.01 versus capsaicin (n = 6). C and D: Plasma GLP-1 levels after 30-min oral glucose challenge in TRPV1−/− and WT mice. *P < 0.05 versus control (Cont) (n = 4). E: Immunoblot data showing GLP-1 protein levels in the mouse ileum after a 24-week administration of dietary capsaicin. *P < 0.05, **P < 0.01 versus control (n = 3). These data are represented as mean ± SEM and were analyzed with a Student unpaired t test.

Chronic dietary capsaicin lowers ambulatory blood glucose levels in a TRPV1-dependent manner.

Blood glucose levels vary widely with food intake during a typical day, but routine blood glucose measurements cannot show changes in the trends of blood glucose levels. This study presented an ambulatory change in blood glucose levels in mice using a CGMS (Medtronic MiniMed) (Fig. 5A–D). The percentages of time that blood glucose levels were either >10.0 mmol/L or <3.9 mmol/L during a 24-h recording period were also calculated (Fig. 5I and J). The mean 24-h blood glucose level was lower in WT mice with chronic dietary capsaicin than those without capsaicin (Fig. 5E). In addition, a lower percentage of time >10.0 mmol/L and a higher percentage of time <3.9 mmol/L were observed in WT mice with chronic dietary capsaicin (Fig. 5G, I, and J). By contrast, no difference was observed in TRPV1−/− mice for either the mean 24-h blood glucose level or the percentage of time >10.0 mmol/L (Fig. 5F, H, and I); percentages of time <3.9 mmol/L were fewer (Fig. 5J). These results indicate that TRPV1 deletion led to an increase in the mean 24-h blood glucose levels and that dietary capsaicin decreased the mean blood glucose levels in a TRPV1-dependent manner.

FIG. 5.

Long-term dietary capsaicin (Cap) administration lowers the mean 24-h blood glucose levels in a TRPV1-dependent manner. AD: Representative daily blood glucose profiles were determined using a MiniMed glucose sensor for the TRPV1−/− or WT mice fed a normal diet or a diet with capsaicin (0.01%); n = 6. E and F: The mean 24-h blood glucose levels in TRPV1−/− or WT mice fed a diet with or without capsaicin for 24 weeks. *P < 0.05 versus control (Cont) (n = 6). G and H: More than 3-day glucose profiles measurements using a MiniMed glucose sensor for the TRPV1−/− or WT mice. I and J: The times when the blood glucose levels were >10.0 mmol/L or <3.9 mmol/L in the TRPV1−/− and WT mice treated with or without capsaicin. *P < 0.05, **P < 0.01 versus WT control (n = 6). These data are represented as mean ± SEM and were analyzed with a Student unpaired t test.

Chronic dietary capsaicin improves abnormal glucose homeostasis in db/db mice.

The db/db mouse is characterized by obesity, insulin resistance, and T2DM (36). We previously reported a lower expression of TRPV1 in visceral adipose tissue from these mice (37). In this study, we explored the effects of dietary capsaicin on body weight, insulin resistance, and blood glucose levels in diabetic mice. Eight-week-old db/db mice were fed a 0.01% capsaicin diet for 14 weeks, and they responded aversively to capsaicin diet during the first 2 weeks (Supplementary Fig. 7A). Chronic dietary capsaicin reversed weight gain (Supplementary Fig. 7B), improved insulin sensitivity in db/db mice (Fig. 6A and Supplementary Fig. 7C), and lowered fasting blood glucose levels (Fig. 6B). After 30 min of an oral glucose (2 g/kg) challenge, plasma GLP-1 and insulin levels were higher in db/db mice treated with dietary capsaicin than in control db/db mice (Fig. 6C and D and Supplementary Fig. 7D). In contrast to hypertrophic and fibrosis islets with low insulin intensity in the control db/db mice, islets exhibited stronger insulin intensity and no fibrosis in capsaicin-treated db/db mice (Fig. 6E). Chronic dietary capsaicin also increased GLP-1 and TRPV1 expression in the distal ileum of db/db mice (Fig. 6E and F). These results suggest that dietary capsaicin improved the abnormal glucose homeostasis in db/db mice through a TRPV1-mediated increase in GLP-1 production.

FIG. 6.

TRPV1 activation increases GLP-1 secretion and restores insulin secretion in db/db mice. A: An intraperitoneal insulin tolerance test in db/db mice treated with or without dietary capsaicin (cap) for 14 weeks; *P < 0.05 versus control (cont) (n = 6). B: The fasting blood glucose levels in db/db mice treated with or without dietary capsaicin for 14 weeks. *P < 0.05, **P < 0.01 versus control (n = 6). C: The GLP-1 (7–36) levels after 30-min oral glucose challenge in db/db mice; *P < 0.05 versus control (n = 6). D: The plasma insulin levels after 30-min oral glucose challenge in db/db mice, *P < 0.05 versus control (n = 6). E: Immunohistochemical analysis of pancreatic sections. The db/db mice and control mice were treated with or without 0.01% capsaicin at indicated dosages for 14 weeks. Pancreas consecutive sections were stained with hematoxylin and eosin. Staining of the insulin using anti-insulin antibody (green) are representative islets from each groups. F and G: Immunoblot data showing GLP-1 and TRPV1 expression levels in db/db mouse ileum tissue after 14 weeks of dietary capsaicin administration. *P < 0.05 versus control (n = 3). These data are represented as mean ± SEM and were analyzed with a Student unpaired t test. (A high-quality digital representation of this figure is available in the online issue.)

DISCUSSION

The current study showed that TRPV1 is localized in intestinal cells and tissues that secrete GLP-1. Capsaicin administration stimulated GLP-1 secretion from STC-1 cells in a calcium-dependent manner through TRPV1 activation. We demonstrated for the first time that acute capsaicin administration by gastric gavage increased GLP-1 and insulin secretion in vivo in WT mice but not in TRPV1−/− mice. Furthermore, chronic dietary capsaicin not only increased plasma GLP-1 and insulin levels, but also improved glucose tolerance and lowered daily blood glucose profiles in WT mice, although these effects were absent in TRPV1−/− mice. In db/db mice, activation of TRPV1 by dietary capsaicin ameliorated the abnormal glucose homeostasis, elevated GLP-1 production in the distal ileum, and increased plasma GLP-1 levels.

Currently, disappointing side effects, contraindications, and minimal improvements in β-cell function highlight urgent need for searching newer therapies, although traditional antidiabetic agents play a role in the management of T2DM (4,5). A GLP-1–based therapy with good glucose control and a low risk of hypoglycemia is an attractive treatment option. GLP-1 is released by L-cells of the intestine upon food ingestion and plays an important role in glucose-dependent insulin secretion, gastric emptying, appetite control, and postprandial reduction of glucagon secretion (38). In this study, we showed oral capsaicin slightly increased the GLP-1 secretion in the absence of glucose challenge. Besides the clinical application of synthetic GLP-1 agonists, another promising option for promoting endogenous GLP-1 production is through dietary or nutrient intervention (11,39). Several studies demonstrated that consumption of dietary chili pepper may reduce blood glucose and attenuate postprandial hyperinsulinemia (24). Capsaicin administration increases glucose absorption from the gastrointestinal tract and increases glucagon release during glucose loading in humans (17). Capsaicin is a specific activator for TRPV1, a nonselective cation channel that is highly Ca2+-permeable (20). TRPV1 is abundantly expressed in sensory neurons but is also detected in nonneuronal cells (25). This study also demonstrated that TRPV1 is expressed in STC-1 cell line and in distal ileum, both of which secrete GLP-1.

However, there are conflicting reports about the role of TRPV1 in the regulation of glucose homeostasis (35). TRPV1+ sensory neurons are important elements of the diabetes pathoetiology in type 1 diabetic mice (22). Capsaicin-sensitive sensory fibers in the islets of Langerhans contribute to defective insulin secretion in the Zucker diabetic rats (40). Capsaicin is known to stimulate the release of calcitonin gene related peptide from perivascular sensory nerve terminals (29). The administration of a TRPV1 antagonist enhanced β-cell function and reduced plasma calcitonin gene–related peptide levels in ob/ob mice (41). By contrast, it has also been reported that capsaicin dose-dependently increased insulin secretion from RIN cells, which was blocked by TRPV1 antagonist (18). Capsaicin increased insulin secretion in incubated pancreatic minces from WT but not TRPV1−/− mice (42). In addition, insulin enhanced the TRPV1 expression and function in heterologous expression systems through the phosphatidylinositol 3-kinase, mitogen-activated protein kinase, and protein kinase C pathways (26). An acute meal that contained capsaicin increased GLP-1 levels without affecting satiety, energy expenditure, or PYY levels in humans (14). Our previous studies showed that capsaicin-activated adipose TRPV1 reversed dietary obesity in mice, and stimulation of endothelial TRPV1 relaxed blood vessels and lowered blood pressure in genetically hypertensive rats (29,37,43). This evidence indicates that nonneuronal TRPV1 has functions that are distinct from neuronal TRPV1, such as glucose regulation.

Several studies showed that GLP-1 is secreted from STC-1 cells through depolarization-induced calcium influx (44). Physiological concentrations of GLP-1 stimulated the insulin secretion, which requires cytosolic calcium increase but was independent of the cAMP-dependent protein kinase (45). Our data showed that capsaicin-induced release of GLP-1 from STC-1 cells could be inhibited by several TRPV1 antagonists. Furthermore, either chelating intracellular calcium or omitting extracellular calcium abolished the capsaicin-induced GLP-1 secretion, suggesting that the GLP-1 release was causally associated with TRPV1-mediated calcium influx. This study also indicated that L-type Ca2+ channel is partially involved in capsaicin-mediated GLP-1 secretion, which could be related to the nonselective nature of TRPV1 for both Ca2+ and Na+ influx, then causing membrane depolarization to activate L-type Ca2+ channels (46). As a proof of principle, we demonstrated that both acute and chronic capsaicin administration increased plasma insulin and GLP-1 levels in WT but not in TRPV1−/− mice. The circulating GLP-1 responses following a glucose challenge were significantly reduced by 32% in TRPV1−/− mice compared with WT mice.

It is very difficult to gauge the magnitude of direct or indirect effect of TRPV1 mediated effect. Under this circumstance, we examined the plasma insulin levels in the absence of glucose challenge. Gastric gavage administration of capsaicin significantly increased the plasma levels of insulin by 30.3% compared with its control, but this effect was significantly inhibited by GLP-1 receptor antagonist-exendin (9–39). Pretreatment with exendin (9–39), capsaicin increased the plasma levels of insulin by 15.9% compared with exendin (9–39) alone (Supplementary Fig. 4B). Our study suggested that TRPV1 activation by capsaicin lowers blood glucose through both a direct action on insulin secretion in the islet and an indirect effect on the gut secretion of GLP-1.

In addition, we further determined whether capsaicin administration could lower blood glucose levels and increase plasma GLP-1 levels in db/db mice, a well-established mouse model for diabetes. A GLP-1 agonist was reported to attenuate hyperglycemia in diabetic animals (47). We showed that chronic administration of capsaicin increased GLP-1 production and insulin secretion, reduced fasting glucose levels, improved insulin sensitivity, and upregulated the expressions of TRPV1 and GLP-1 in the ileum of db/db mice. The present results indicate that a dietary capsaicin intervention can ameliorate abnormal glucose homeostasis and partially restore β-cell function in diabetic mice.

Clinical studies show that combination therapy with sitagliptin and other drugs were generally well-tolerated and safety (48). Almost no or minor drug–drug interactions has been reported between DPP-4 inhibitors and other drugs (48). It is unknown whether there is interaction between capsaicin and DPP-4 inhibitors. Several studies show that capsaicin, but not DPP-4 inhibitors (except saxagliptin), can inhibit cytochrome P450 (CYP 3A4/A5) enzymes (4850). Thus, in general, interactions between DPP-4 inhibitors and capsaicin are absent or minor. However, more well-controlled clinical studies are needed to evaluate the safety and long-term effect of these drugs.

In summary, the current study demonstrates that chronic dietary capsaicin effectively increases GLP-1 secretion from both intestinal cells and tissues, and such benefit is related to calcium influx mediated by TRPV1 activation. Capsaicin treatment improves glucose homeostasis and insulin sensitivity in diabetic mice. Taken together, dietary capsaicin may represent a promising lifestyle intervention for populations at a high risk for developing diabetes.

ACKNOWLEDGMENTS

This research was supported by grants from the National Basic Research Program of China (2012CB517805 and 2011CB503902 to Z.Zhu and D.L.) and National Natural Science Foundation of China (30890042, 81130006, 30670976, and 31071006 to D.L., Z.Y., and Z.Zhu). This work was also supported by the Program for Changjiang Scholars from the Ministry of Education in China (to Z.Zhu).

No potential conflicts of interest relevant to this article were reported.

P.W. performed most of the experiments, analyzed data, and wrote the manuscript. Z.Y. and J.C. performed some experiments and edited the manuscript. J.Z. reviewed and edited the manuscript. Y.N. performed some experiments and contributed to the discussion. L.L., L.M., and Z.Zhao performed some experiments. D.L. edited the manuscript and contributed to the discussion. Z.Zhu designed the experiments, wrote and edited the manuscript, and is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

The authors thank Tingbing Cao, Zhidan Luo, and Lijuan Wang (Chongqing Institute of Hypertension, China) for technical assistance. The authors also thank Prof. Yu Huang and Dr. Wing Tak Wong (Chinese University of Hong Kong, China) for critical review of the manuscript.

  • Received October 26, 2011.
  • Accepted April 12, 2012.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

REFERENCES

| Table of Contents

This Article

  1. Diabetes vol. 61 no. 8 2155-2165
  1. Supplementary Data
  2. All Versions of this Article:
    1. db11-1503v1
    2. 61/8/2155 most recent